Trial Profile
A Phase I, Open-label, Randomized, Four-period, Crossover, Single Center Trial to Assess the Relative Bioavailability of a Single Oral Dose of the New 150 mg Oral Dispersible Tablet (ODT) Formulation of Praziquantel (PZQ), MSC1028703A, at Different Dose Levels vs the Current Commercial 500 mg Tablet Formulation of PZQ in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Praziquantel (Primary)
- Indications Schistosomiasis
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 19 Apr 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Jan 2015 New trial record